Evidence map›Paper›PMID 26782825›Full record

ReviewCurrent atherosclerosis reports2016

Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.

Ashish Sarraju, Sun H Kim, Joshua W Knowles

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ashish SarrajuDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Sun H KimDivision of Endocrinology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Joshua W KnowlesDivision of Cardiovascular Medicine and Cardiovascular Institute, Stanford University School of Medicine, Falk CVRC, Room CV273, MC 5406, 300 Pasteur Drive, Stanford, CA, 94305, USA. knowlej@stanford.edu.
Stanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease is the leading cause of death among adults in the USA. Both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) are known risk factors for cardiovascular disease. Despite the development of numerous effective anti-glycemic therapies, we have been unable to completely mitigate cardiovascular risk with glucose lowering alone, and prevention of cardiovascular disease in patients with diabetes is primarily achieved with the use of medications that address other risk factors such as anti-hypertensives or statins. Glucagon-like peptide-1 (GLP-1) is a key hormone in the pathophysiology of diabetes. GLP-1 agonists have been recently approved for the treatment of T2DM as well as for chronic weight management. In this review, we aim to explore the effects of GLP-1 agonists on cardiovascular health with a focus on cardiometabolic variables and cardiac function.

Indexed as

Cardiovascular DiseasesEndotheliumGlucagon-Like Peptide 1HumansRisk FactorsTreatment OutcomeGlucagon-Like Peptide 1ASCVD risk factorsAtherosclerosisCardiovascular diseaseDiabetesGLP-1 agonistsGlucagon-like peptide-1Heart failureMortality

Identifiers

PMID26782825
OpenAlexW2292763234

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.